Cagnacci Angelo, De Toni Anna, Caretto Simona, Menozzi Renata, Bondi Mario, Corradini Barbara, Alessandrini Chiara, Volpe Annibale
Department of Obstetrics Gynaecology and Paediatrics, Policlinico di Modena, Modena, Italy.
Menopause. 2006 Mar-Apr;13(2):197-201. doi: 10.1097/01.gme.0000174469.37198.a0.
The menopause transition is characterized by luteal phase defect anovulatory cycles, and changes in body weight and body composition. Resting metabolic rate (RMR) is increased in the luteal phase of the menstrual cycle. We evaluated whether progestin administration increases RMR and influences body composition of perimenopausal women.
Thirty-six perimenopausal women were randomly allocated to receive either calcium (1 g/day) continuously plus the progestin nomegestrol acetate (NOMAc; 5 mg/day for 10 days x month for 12 months) or calcium alone. Body composition, RMR, energy intake, and climacteric and psychological symptoms were evaluated at baseline and after 12 months. In the NOMAc group, body composition and RMR analyses were performed twice during the first month of treatment. One evaluation was performed after almost 8 days of NOMAc adjunct, and an another before or almost 15 days after NOMAc administration.
Resting metabolic rate was increased by NOMAc administration of 54.5 +/- 73.8 kcal/24 h (P < 0.01). In women treated with NOMAc, fat mass decreased by 1.2 +/- 0.6 kg (P < 0.001). In comparison with controls, body weight (P < 0.05) and body mass index (P < 0.05) were also reduced after 12 months of therapy with NOMAc.
In perimenopausal women the use of NOMAc increases RMR. During the menopause transition, cyclic NOMAc administration may contribute to reduce negative modification of body composition.
围绝经期过渡的特征是黄体期缺陷、无排卵周期以及体重和身体成分的变化。静息代谢率(RMR)在月经周期的黄体期会升高。我们评估了孕激素给药是否会增加围绝经期女性的RMR并影响其身体成分。
36名围绝经期女性被随机分配,分别连续接受钙(1克/天)加孕激素诺美孕酮醋酸酯(NOMAc;5毫克/天,每月10天,共12个月)或仅接受钙治疗。在基线和12个月后评估身体成分、RMR、能量摄入以及更年期和心理症状。在NOMAc组中,在治疗的第一个月内对身体成分和RMR进行了两次分析。一次评估在NOMAc辅助治疗近8天后进行,另一次在NOMAc给药前或给药后近15天进行。
给予NOMAc后静息代谢率增加了54.5±73.8千卡/24小时(P<0.01)。接受NOMAc治疗的女性脂肪量减少了1.2±0.6千克(P<0.001)。与对照组相比,接受NOMAc治疗12个月后体重(P<0.05)和体重指数(P<0.05)也有所降低。
在围绝经期女性中,使用NOMAc可增加RMR。在围绝经期过渡期间,周期性给予NOMAc可能有助于减少身体成分的负面改变。